Back to Search
Start Over
Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC.
- Source :
-
OncoImmunology . 2017, Vol. 6 Issue 4, pN.PAG-N.PAG. 1p. - Publication Year :
- 2017
-
Abstract
- Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 macrophages (Mφ) play a key role in host antitumor defenses in HCC. In our study, CD14+cells were isolated from the peripheral blood of four groups of HCC patients (group-1, patients with stage 0 HCC; group-2, patients with stage A HCC; group-3, patients with stage B HCC; and group-4, patients with stage C HCC) and characterized phenotypically. Then, CD14+cells from group-2 and group-3 HCC patients were induced to polarize and tested for their antitumor abilities in a chimera model of HCC patients. Human HCCs (HepG2 solid tumors) grew in a chimera model of group-3 patients (group-3 HCC chimeras) but not in a chimera model of group-2 patients (group-2 HCC chimeras). In response to HCC antigens, the majority of CD14+cells from group-2 patients (group-2 CD14+cells) switched to the M1 phenotype (IL-12+IL-10−iNOS+cells), whereas the majority of CD14+cells from group-3 patients (group-3 CD14+cells) did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12−IL-10+CCL1+iNOS−cells). Group-3 CD14+cells showed M1Mφ polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of group-3 HCC chimeras are improved after CCL1 antisense ODN treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- *LIVER cancer
*MACROPHAGES
*DRUG resistance in cancer cells
*PHYSIOLOGY
Subjects
Details
- Language :
- English
- ISSN :
- 21624011
- Volume :
- 6
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- OncoImmunology
- Publication Type :
- Academic Journal
- Accession number :
- 122728732
- Full Text :
- https://doi.org/10.1080/2162402X.2017.1299301